Juvenile Arthritis News

Although the current net price of adalimumab biosimilar Amjevita is lower for commercial health plans than that of the originator, it is nonetheless “more than double” what Humira cost at launch in 2003, according to a research letter.

The FDA has approved Tofidence as the first tocilizumab biosimilar in the United States for the treatment of rheumatoid arthritis and other conditions, according to a statement from the manufacturer.

Patients with juvenile idiopathic arthritis who receive baricitinib demonstrate a “significantly” longer time to disease flare vs. placebo, according to data published in The Lancet.

Infants who demonstrate microbiome dysregulation may be at a higher risk for juvenile idiopathic arthritis, according to data published in eBioMedicine.

A program using cognitive behavioral and mindfulness meditation techniques demonstrated early potential to ease fatigue, depression and pain symptoms in childhood-onset systemic lupus erythematosus, according to researchers.

SAN DIEGO — The recent approvals of belimumab, golimumab, tofacitinib, secukinumab and ustekinumab in children with rheumatic diseases, all within the past 4 years, have changed the landscape in pediatric rheumatology, noted a speaker here.

Knee acoustic emissions may be an “inexpensive and easy-to-use” biomarker to help differentiate between patients with and without juvenile idiopathic arthritis, according to data published in Pediatric Rheumatology.

AUSTIN, Texas — Research in genetics as it relates to rheumatologic diseases has a long way to go, but there are steps providers can take to translate current knowledge into actionable patient care, a presenter said.

Leonard Calabrese, DO, chief medical editor of Healio Rheumatology, offered a breakdown of the June issue, which is led by a cover story on pediatric rheumatology workforce shortage concerns.

Cyltezo, the first interchangeable Humira biosimilar, officially entered the U.S. market on July 1, opening a floodgate that will see the release this month of half a dozen biosimilars for what has been the top selling drug in the country.